Tizaterkib

DB21296InvestigationalSmall molecule

Tizaterkib is a small molecule drug. The usage of the INN stem '-terkib' in the name indicates that Tizaterkib is a extracellular signal-regulated kinase (ERK) inhibitor. Tizaterkib is under investigation... Tizaterkib is under investigation in clinical trial NCT04305249 (Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies).

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 1 and Mitogen-activated protein kinase 3
Curator reviewed
Formula / weight: C₂₄H₂₄F₂N₈O₂ · 494.507 g/mol (avg)
Code names: ATG-017 · AZ-13820216 · AZD-0364

Resolves to

Compound

UNIIVO9KX45QIQCAS2097416-76-5ChEMBLCHEMBL4482864

Structure

InChIKeyHVIGNZUDBVLTLU-MRXNPFEDSA-NSMILESCOC[C@H]1CN2C=C(N=C2C(=O)N1CC1=CC=C(F)C(F)=C1)C1=NC(NC2=CC=NN2C)=NC=C1C

Targets

P28482MAPK1P27361MAPK3

What you can answer from here — as of September 12, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tizaterkib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account